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Aims The co-transmitter neuropeptide-Y (NPY) is released during high sympathetic drive, including ST-elevation myocar-
dial infarction (STEMI), and can be a potent vasoconstrictor. We hypothesized that myocardial NPY levels correl-
ate with reperfusion and subsequent recovery following primary percutaneous coronary intervention (PPCI), and
sought to determine if and how NPY constricts the coronary microvasculature.
...................................................................................................................................................................................................
Methods and
results
Peripheral venous NPY levels were significantly higher in patients with STEMI (n= 45) compared to acute coronary syn-
dromes/stable angina ( n= 48) or with normal coronary arteries (NC, n= 16). Overall coronary sinus (CS) and periph-
eral venous NPY levels were significantly positively correlated (r= 0.79). STEMI patients with the highest CS NPY levels
had significantly lower coronary flow reserve, and higher index of microvascular resistance measured with a coronary
flow wire. After 2 days they also had significantly higher levels of myocardial oedema and microvascular obstruction on
cardiac magnetic resonance imaging, and significantly lower ejection fractions and ventricular dilatation 6 months later.
NPY (100–250 nM) caused significant vasoconstriction of rat microvascular coronary arteries via increasing vascular
smooth muscle calcium waves, and also significantly increased coronary vascular resistance and infarct size in
Langendorff hearts. These effects were blocked by the Y1 receptor antagonist BIBO3304 (1lM). Immunohistochemistry
of the human coronary microvasculature demonstrated the presence of vascular smooth muscle Y1 receptors.
...................................................................................................................................................................................................
Conclusion High CS NPY levels immediately after reperfusion correlate with microvascular dysfunction, greater myocardial in-
jury, and reduced ejection fraction 6 months after STEMI. NPY constricts the coronary microcirculation via the Y1
receptor, and antagonists may be a useful PPCI adjunct therapy.
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Introduction
The rapid re-opening and stenting of occluded epicardial coronary
arteries via emergency primary percutaneous coronary interven-
tion (PPCI) has revolutionized the treatment of ST-elevation myo-
cardial infarction (STEMI). Despite technical refinements to the
procedure and the introduction of numerous antiplatelet and anti-
coagulant medications, around one-third of patients demonstrate
‘no-reflow’ due to flow limitation in small intramyocardial arteries
and arterioles beyond the point of the stenting known as the
‘microcirculation’. This is associated with persistent ST-elevation,
larger infarct size, lower ejection fraction, and worse prognosis.1
Patients with a high index of microcirculatory resistance (IMR),2
or with persistently low coronary flow reserve (CFR)3 following
PPCI measured using a coronary pressure wire, have larger
infarcts and lower ejection fractions. Microvascular obstruction
can also be directly imaged using contrast-enhanced cardiac mag-
netic resonance imaging (CMR) and its presence strongly predicts
infarct size and adverse prognosis.4 Distal athero-thrombotic em-
bolization from the ruptured plaque and thrombus5 may contrib-
ute to poor microcirculatory perfusion although clinical trials of
thrombectomy at the time of PPCI have failed to demonstrate
consistent improvements in outcome.6 Functional vasoconstric-
tion in the coronary microvasulature may also contribute to poor
microvascular flow, but the mechanisms are poorly understood.
Commonly used vasodilator drugs such as adenosine and sodium
nitrprusside have not demonstrated clinical benefit,7 suggesting
that these mechanisms remain to be identified. It is likely that
there are reversible as well as irreversible components to micro-
vascular obstruction, the former of which could provide new
therapeutic targets.
Acute myocardial infarction is associated with high levels of car-
diac sympathetic drive, which is a poor prognostic indicator.8
Prolonged sympathetic activation causes the release of the co-
transmitter neuropeptide-Y (NPY),9 which can cause vasocon-
striction in a variety of vascular beds.10 When infused directly into
coronary arteries in humans, NPY can induce chest pain and is-
chaemic electocardiogram (ECG) changes presumably from
microvascular constriction.11 We have shown that peripheral ven-
ous levels of NPY are significantly elevated in patients undergoing
PPCI following STEMI and remain high for at least 48 h.12 Clinical
studies before the advent of PPCI and modern medical treatment,
have also shown that peripheral venous ‘NPY-like activity’ is ele-
vated during ischaemic events and correlates with 1-year mortal-
ity.13 However, hepato-mesenteric release also contributes
significantly to circulating levels of ‘NPY-like activity’,14 making
peripheral venous sampling less accurate in determining local car-
diac NPY concentrations.
We, therefore, hypothesized that coronary sinus (CS) levels of
NPY would provide a close correlation with measurements of reper-
fusion and microvascular obstruction in STEMI patients undergoing
PPCI, and may determine the degree to which myocardial function
recovers. Further to investigate possible causation, we tested
whether NPY vasoconstricts the coronary microvasculature and
increases infarct size in the rat, and then explored the receptor path-
ways involved to assess whether these may be applicable for human
pharmacological intervention.
Methods
See Supplementary material online for expanded Methods. This study
complies with the Declaration of Helsinki and was approved by local eth-
ics committee (REC: 10/H0408/24 and 10/H0606/36). All participants
gave written informed consent. Patients were recruited as part of the
Oxford Acute Myocardial Infarction (OxAMI) study. Animal use com-
plied with the University of Oxford local ethical guidelines and the
Animals (Scientific Procedures) Act 1986 (UK).
Results
Peripheral venous and coronary sinus
neuropeptide-Y levels in patients with
normal coronary arteries, stable angina,
acute coronary syndromes, and ST-
elevation myocardial infarction
45 patients with acute left coronary artery STEMI (presenting
throughout the 24-h cycle of clinical activity) underwent peripheral
venous and CS blood sampling immediately after completion of PPCI.
NPY levels were compared with 48 patients who were pain-free and
undergoing non-emergency coronary angiography for stable angina
(SA) or acute coronary syndromes (ACS) and a group of 16 patients
undergoing elective coronary angiography who were found to have
normal coronary arteries (NC). The patients demographics, admis-
sion medications, and haemodynamics at the time of angiography are
summarized in Table 1. Patients were of similar age with similar car-
diovascular risk factors, although significantly fewer STEMI patients
had a diagnosis of hyperlipidaemia at presentation. Significantly fewer
STEMI patients were taking beta-blockers, angiotensin converting en-
zyme inhibitors/angiotensin receptor antagonists, or a statin at pres-
entation. Moreover, patients presenting with STEMI who were in
pain at the time of PPCI had significantly higher heart rate and diastol-
ic blood pressure. As expected, patients with STEMI had the highest
peak troponin rise followed by those experiencing SA/ACS with
those with NC having minimal troponin rise.
The levels of peripheral venous and CS NPY in the three groups
are summarized in Figure 1. Overall paired CS and peripheral venous
NPY were significantly positively correlated (r= 0.79, n= 64,
P< 0.0001) as shown in Figure 1C. Peripheral venous and CS levels of
NPY were similar in the SA/ACS and NC groups, as shown in Figure
1A and B. Patients with STEMI had three-fold higher CS NPY levels
than those with SA/ACS or NC. We used this to define the lower
tertile of the STEMI group as having low CS NPY levels (n= 15), simi-
lar to those with NC and SA/ACS [12.9 (9.0–14.9) vs. NC/SA/ACS:
10.0 (1.8–12.4 pg/mL)], and the middle and upper tertiles as having
high CS NPY levels (n= 30), shown by the dotted line in Figure 1C.
Invasive measures of microvascular
function in STEMI patients with high vs.
low coronary sinus neuropeptide-Y levels
The baseline characteristics of STEMI patients with low and high CS
NPY levels are summarized in Table 2. The two groups were well
matched in terms of age, sex, cardiovascular risk factors, medications,
and haemodynamics on admission. They had similar TIMI flow and
pain to balloon time at presentation. There was no significant correl-
ation between CS NPY levels and pain to balloon time (r= 0.24,
2 N. Herring et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz115/5374846 by U
niversity of Bristol Library user on 13 M
ay 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..P= 0.1). Although levels of CS NPY were significantly different be-
tween the groups, levels of CS endothelin-1 were similar and there
was no significant correlation between CS NPY and endothelin-1 lev-
els (r= 0.001, P= 0.81).
Immediately after stent implantation and post-dilatation, invasive
measurements of coronary microcirculatory function were taken
using a pressure wire. Coronary haemodynamic measures are sum-
marized in Table 3. Patients with high CS NPY levels had significantly
lower CFR and a significantly higher IMR. This relationship did not
reach significance when considering low vs. high peripheral venous
NPY (CFR 1.84 ± 0.88 vs. 1.52± 0.55, P= 0.22; IMR 35.2 ± 18.7 vs.
43.2± 31.2, P= 0.29) or low vs. high CS endothelin-1 (CFR
1.62± 0.75 vs. 1.63 ± 0.66, P= 0.94; IMR 50.1± 38.3 vs. 35.7± 19.5,
P= 0.19). In a subset of patients a collateral pressure index was also
measured, although there was no significant difference between
patients with low v’s high CS NPY (0.16 ± 0.09, n= 7 vs. 0.15±0.07,
n= 10).
Imaging measures of microvascular
function and cardiac recovery in STEMI
patients with high vs. low coronary sinus
neuropeptide-Y levels
Two days following PPCI, all patients underwent CMR and there was
no difference in the time to scan between those patients with low vs.
high CS NPY [41.5 (33.8–47.3) vs. 48.0 (28.5–49.0) h, P= 0.38]. This
demonstrated similar left ventricular dimensions and ejection fraction
in the high and low CS NPY groups at this stage. However, there was
a significantly larger volume of myocardial oedema in those patients
with high CS NPY levels and a significantly greater volume of micro-
vascular obstruction. Six months following STEMI a further CMR
scan demonstrated a significantly lower ejection fraction in those
with high CS NPY compared to those with low CS NPY levels
(50.5 ± 11.8, n= 12, vs. 61.7± 3.8%, n= 23, P< 0.0001) and signifi-
cantly dilated left ventricular volumes as shown in Table 4. Overall CS
NPY levels were positively correlated with infarct size (by late gado-
linium enhancement) at 6 months (r= 0.46, P= 0.01) as was acute
microvascular obstruction (r= 0.55, P= 0.003). However, on multi-
variate analysis, acute microvascular obstruction was an independent
predictor of infarct size (P= 0.01) above CS NPY, in keeping with CS
NPY causing larger infarcts via worsening microvascular obstruction.
The relationship with infarct size, ejection fraction and left ventricular
volumes did not reach significance when considering high vs. low per-
ipheral venous NPY (ejection fraction 51.7± 11.6 vs. 58.8± 9.6%,
P= 0.12).
The action of neuropeptide-Yon
microvascular coronary arteries and
Langendorff perfused hearts
In order to investigate the mechanistic importance of high myo-
cardial NPY in mediating coronary microvascular dysfunction, we
tested the direct effects of NPY on microvascular coronary
arteries. NPY (100 nM, n= 6) caused calcium waves in vascular
smooth muscle cells (Figure 2A–C) and dose dependent vasocon-
striction of isolated microvascular coronary arteries (significant at
100 and 250 nM, n= 6, Figure 2D), which could be prevented by
the Y1 receptor antagonist BIBO3304 (1 lM) without changing
....................................................................................................................................................................................................................
Table 1 Patient demographics according to clinical diagnosis (peripheral venous blood)
NC
(n5 16)
SA/ACS
(n5 48)
STEMI
(n5 45)
P-value P-value
(NC vs.
SA/ACS)
P-value
(NC vs. S
TEMI)
P-value
(SA/ACS vs.
STEMI)
Age (years) 67 ± 12 65 ± 12 63 ± 13 0.39 1.00 0.59 1.00
Males 10/16 (63) 36/48 (75) 35/45 (77.8) 0.48 0.35 0.32 0.81
Cardiovascular risk factors
Hypertension 13/16 (81) 32/48 (67) 19/45 (42.2) 0.36 0.35 1.00 0.36
Hyperlipidaemia 9/16 (56) 41/48 (85) 16/45 (35.6) <0.0001 0.031 0.24 <0.0001
Diabetes mellitus 3/16 (19) 10/48 (21) 6/45 (13.3) 0.63 1.00 0.69 0.42
Current smoker 2/16 (13) 13/48 (27) 19/45 (42.2) 0.06 0.32 0.037 0.13
Ex-smoker 8/16 (50) 21/48 (43) 19/45 (42.2) 0.86 0.77 0.77 >0.9999
Family history 8/16 (50) 22/48 (46) 19/45 (42.2) 0.85 0.78 0.77 0.84
Medications on admission
Beta-blockers 10/16 (63) 27/48 (56) 4/45 (8.9) <0.0001 0.77 <0.0001 <0.0001
ACE inhibitor/ATR antagonist 11/16 (69) 31/48 (65) 7/45 (15.6) <0.0001 1.00 0.0002 <0.0001
Statin 14/16 (88) 39/48 (81) 8/45 (17.8) <0.0001 0.72 <0.0001 <0.0001
Blood pressure and heart rate
Systolic (mmHg) 130.3 ± 27.8 125.9 ± 22.7 135.3 ± 27.3 0.23 1.00 1.00 0.26
Diastolic (mmHg) 64.1 ± 10.2 69.3 ± 11.1 81.4 ± 17.9 <0.0001 0.78 0.001 0.0005
Heart rate (/min) 66.4 ± 14.4 69.2 ± 13.7 79.6 ± 21.7 0.008 1.00 0.05 0.02
Peak Troponin I (mg/L) 0.3 ± 0.6 3.8 ± 12.4 40.7 ± 16.2 <0.0001 1.00 <0.0001 <0.0001
Values are expressed mean ± SD or n (%).
ACS, acute coronary syndromes; NC, normal coronary arteries; SA, stable angina; STEMI, ST-elevation myocardial infarction.
Neuropeptide-Y and microvascular perfusion in STEMI 3
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myogenic tone (Figure 2E). In the Langendorff perfused heart, NPY
(250 nM, n= 6) caused a significant increase in coronary vascular
resistance (Figure 2F) that could also be prevented by the Y1 re-
ceptor antagonist BIBO3304 (1 lM, n= 6) but not the Y2 receptor
antagonist BIIE0246 (1 lM, n= 6). NPY (250 nM, n= 10) also sig-
nificantly increased infarct size in relation to the area at risk during
left coronary artery ischaemia reperfusion compared with control
hearts (n= 10), and this could also be prevented by the Y1 recep-
tor antagonist BIBO3304 (1 lM, n= 6) as shown in Figure 3.
Neuropeptide-Y Y1 receptor is present in
the human coronary microvasculature
We obtained samples of human myocardium during cardiothoracic
surgery from which we dissected coronary micro-arteries.
Immunohistochemistry demonstrated the presence of the Y1
receptor on vascular smooth muscle cells in the media of the vessels
as shown in Figure 4.
Discussion
This is the first study to measure CS NPY levels in patients under-
going PPCI and demonstrate a link with microvascular obstruction,
infarct size, and subsequent cardiac recovery at 6 months in terms of
ejection fraction. In addition it is the first study to show that NPY
constricts the coronary microvasculature via Y1 receptor dependent
calcium mobilization and demonstrate the utility of blocking this re-
ceptor in reducing coronary vascular resistance and limiting infarct
size. Importantly, the Y1 receptor is expressed on vascular smooth
muscle cells in the media of human coronary micro-arteries making it
a suitable target for pharmacological intervention.
Figure 1 Relationship between peripheral venous and coronary sinus neuropeptide-Y. Peripheral venous (A) concentrations of neuropep-
tide-Y in patients with normal coronary arteries (n = 16), stable angina or acute coronary syndromes (n = 48), or ST-elevation myocardial in-
farction (n = 45). (B) Coronary sinus concentrations of neuropeptide-Y in the same groups (normal coronary arteries, n = 4, stable angina or
acute coronary syndromes, n = 15, ST-elevation myocardial infarction, n = 45). (C) There is a strong positive correlation between peripheral
venous and coronary sinus levels across all patient groups when paired samples were taken (r = 0.79, n = 64, P < 0.0001). Both coronary sinus
and peripheral venous levels in the ST-elevation myocardial infarction group were three times higher than those in the stable angina or acute
coronary syndromes groups, and this was used to define the lower tertial of coronary sinus neuropeptide-Y levels in the ST-elevation myocar-
dial infarction group as being low, and the middle and upper tertial as being high as illustrated by the dotted line in (C). NSTEMI, non-ST-eleva-
tion myocardial infarction; UA, unstable angina.
4 N. Herring et al.
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Table 2 Clinical characteristics according to coronary sinus neuropeptide-Y level
Low CS NPY High CS NPY P-value
(n5 15) (n5 30)
Age (years) 58.4 ± 12.9 64.5 ± 12.9 0.14
Males 13/15 (86.7) 22/30 (73.3) 0.46
Cardiovascular risk factors
Hypertension 5/15 (33.3) 14/30 (46.7) 0.53
Hyperlipidaemia 7/15 (46.7) 9/30 (30) 0.33
Diabetes mellitus 3/15 (20) 3/30 (10) 0.65
Current smoker 7/15 (46.7) 12/30 (40) 0.75
Ex-smoker 7/15 (46.7) 12/30 (40) 0.75
Family history 6/15 (40) 13/30 (43.3) 1.00
Medications on admission
Beta-blockers 0/15 (0) 4/30 (13.3) 0.28
ACE inhibitor/ATR antagonist 2/15 (13.3) 5/30 (16.7) 1.00
Statin 3/15 (20) 5/30 (16.7) 1.00
BP and heart rate at presentation
Systolic BP (mmHg) 135.1 ± 4.1 135.4 ± 5.8 0.97
Diastolic BP (mmHg) 82.7 ± 4.0 80.7 ± 3.5 0.71
Heart rate (/min) 78.4 ± 4.0 80.1 ± 4.5 0.77
Pain to balloon time (min) 368 ± 85 244 ± 47 0.21
Infarct artery
LAD 11/15 (73.3) 22/30 (73.3) 1.00
LCx/Int 4/25 (26.7) 8/30 (26.7) 1.00
TIMI flow at presentation
0 11/15 (73.3) 24/30 (80) 0.71
I 1/15 (6.7) 2/30 (6.7) 1.00
II 2/15 (13.3) 3/30 (10) 1.00
III 1/15 (6.7) 1/30 (3.3) 1.00
Peak Troponin I (mg/L) 40.8 ± 16.7 40.6 ± 16.2 0.97
Coronary sinus NPY concentration (pg/mL) 12.9 (9.0–14.9) 29.3 (23.6–51.4) <0.00001
Coronary sinus endothelin-1 concentration (fmol/mL) 3.3 (2.1–22.3) 5.0 (2.0–10.7) 0.87
Values are mean ± SD, median (interquartile range), or n (%). Statistically significant results are in bold.
LAD, left anterior descending artery; LCx, left circumflex artery; Int, intermediate artery.
....................................................................................................................................................................................................................
Table 3 Coronary physiology according to coronary sinus neuropeptide-Y levels
Coronary haemodynamics Low CS NPY High CS NPY P-value
(n5 15) (n5 30)
Baseline fractional flow reserve 0.91 ± 0.06 0.92 ± 0.05 0.37
Hyperaemic fractional flow reserve 0.87 ± 0.08 0.90 ± 0.07 0.11
Baseline transit time (s) 0.87 ± 0.47 0.77 ± 0.37 0.45
Hyperaemic transit time (s) 0.48 ± 0.24 0.60 ± 0.40 0.24
Baseline distal pressure (mmHg) 84.5 ± 14.5 90.9 ± 16.4 0.19
Hyperaemic distal pressure (mmHg) 68.0 ± 13.3 77.0 ± 14.0 0.04
Coronary flow reserve 1.94 ± 0.81 1.47 ± 0.55 0.03
Index of microcirculatory resistance 30.9 ± 12.2 45.3 ± 31.9 0.03
Values are expressed as mean ± SD. Statistically significant results are in bold.
Neuropeptide-Y and microvascular perfusion in STEMI 5
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Coronary sinus and peripheral venous
neuropeptide-Y levels in patients
undergoing coronary angiography
The main source of circulating NPY is sympathetic nerve terminals
and the adrenal medulla and NPY can act as a local neuromodulator
of several aspects of cardiac function.10 NPY may be involved in the
pathogenesis of atherosclerosis,15 in addition to maintaining cardiac
contraction, promoting ventricular hypertrophy,10 and reducing
parasympathetic nerve activity.16 It may also be taken up into mega-
karyocytes and released at sites of vascular remodelling as well as in
the endothelium itself which also contains dipeptidyl peptidase.
There may, therefore, be local autocrine NPY systems at sites of
angiogenesis and vascular remodelling.17 Animal studies suggest that
cardiac NPY is released from sympathetic nerves during experimen-
tally induced myocardial infarction.18 Early studies in the late 1980s,
before modern interventional and pharmacological treatment of
STEMI have shown that peripheral venous ‘NPY-like activity’ is ele-
vated during ischaemic events and correlates with 1-year mortality.13
However, hepato-mesenteric release also contributes significantly to
circulating levels of ‘NPY-like activity’,14 making peripheral venous
sampling less accurate in reflecting cardiac NPY levels. These early
studies only measured ‘NPY like activity’ with very high limits of de-
tection (>90 pg/mL compared to our 2–3 pg/mL). Our assay has 0%
cross-reactivity with structurally similar peptides such as peptide YY,
pancreatic polypeptide, gastric inhibitory polypeptide, ghrelin, pro-
insulin, or glucagon. In patients with normal coronary arteries, we
measure CS NPY levels of 4.5 ± 2.5 pg/mL. By comparison, the me-
dian peripheral venous NPY level in 303 normal adult subjects (using
an assay with a similar level of detection to ours and minimal cross-
reactivity) is <2 pg/mL.19
STEMI patients had higher NPY levels and were also more hyper-
tensive and tachycardic than patients with SA/ACS and NC who were
pain-free at the time of their non-emergency procedure. This is unsur-
prising given that STEMI patients were suffering from chest pain and
would have high levels of sympathetic drive. NPY released during these
conditions can also inhibit parasympathetic neurotransmission and the
ability of the vagus to reduce heart rate.9,16 Elevated NPY levels have
also been observed in animal models20 and patients21 with essential
hypertension. For comparison, venous NPY levels in patients present-
ing with Takotsubo cardiomyopathy with severely impaired systolic
function and massive catecholamine release were around 186 pg/mL.22
In the anesthetized dog, direct stimulation of the cardiac sympa-
thetic innervation leads to the appearance of NPY in CS blood.23 In
patients with cardiac failure or patients with normal hearts undertak-
ing exercise, cardiac release contributes significantly more to circulat-
ing peripheral venous levels than at rest.14 Whilst peripheral venous
and CS levels of NPY are correlated across all three patient groups in
our study, this is driven by the very high levels of NPY measured in
the STEMI group where cardiac NPY release is likely to have equili-
brated with peripheral circulating levels by the time of blood sam-
pling. It is interesting to note that peripheral venous NPY levels are
not significantly different in patients with NC and ACS/SA, whereas
CS NPY levels are higher in the ACS/SA group compared to patients
with NC. Moreover, whilst high CS levels of NPY in the STEMI
groups correlated with indices of reperfusion and 6 month ejection
fraction, this relationship did not reach significance for peripheral ven-
ous levels, suggesting that CS levels may give a more accurate reflec-
tion of the NPY concentration to which the coronary
microvasculature is exposed and subsequently its behaviour.
Coronary sinus neuropeptide-Yand
measures of reperfusion and cardiac
recovery
Contrast-enhanced CMR is considered the gold-standard imaging to
assess microvascular obstruction following myocardial infarction, and
strongly predicts infarct size and prognosis.4 Studies have also corre-
lated an IMR >40 with CMR measures of oedema and microvascular
obstruction as well as a worse ejection fraction and ventricular
....................................................................................................................................................................................................................
Table 4 Cardiac magnetic resonance imaging post-ST-elevation myocardial infarction according to coronary sinus
neuropeptide-Y levels
Cardiac MRI Low CS NPY High CS NPY P-value
(n5 12) (n5 23)
Post-PPCI
Ejection fraction (%) 47.3 ± 8.5 44.6 ± 10.0 0.40
End-diastolic volume (mL) 142.9 ± 48.5 162.9 ± 45.4 0.25
End-systolic volume (mL) 78.1 ± 38.2 92.4 ± 35.8 0.30
Late Gd enhancement (%) 25.2 ± 13.6 34.1 ± 16.3 0.10
Haemorrhage (%) 1.0 ± 1.9 3.6 ± 6.1 0.07
Ventricular oedema (%) 33.4 ± 14.0 44.5 ± 16.2 0.048
Microvascular obstruction (%) 0.22 ± 0.12 1.62 ± 2.52 0.02
6 months
Ejection fraction (%) 61.7 ± 3.8 50.5 ± 11.8 <0.001
End-diastolic volume (mL) 140.9 ± 28.0 173.0 ± 47.3 0.038
End-systolic volume (mL) 54.6 ± 14.7 87.6 ± 38.5 0.003
Values are expressed as mean ± SD. Statistically significant results are in bold.
Gd, gadolinium; MRI, magnetic resonance imaging.
6 N. Herring et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz115/5374846 by U
niversity of Bristol Library user on 13 M
ay 2019
..
..
..
..
.
dilatation at 6 months.24 CMR measures of microvascular obstruction
are also associated with lower CFR.25 Patients with high CS NPY lev-
els have significantly higher IMR, lower CFR, and evidence of
microvascular obstruction and worse ejection fraction at 6 months on
CMR compared to patients with low CS NPY levels. However, the
same relationship did not reach significance for high vs. low peripheral
Coronary vascular resistance
F
Intramuscular coronary artery vasoconstricon
Intramuscular coronary artery calcium
A B C
ED
p<0.0001
p=0.006
p=0.01p=0.61
p=0.08
p=0.91
p=0.31
p>0.99
p>0.99p>0.99
p=0.04
p<0.001
Figure 2 Microvascular coronary artery vasoconstriction with neuropeptide-Y. Neuropeptide-Y (100 nM, n = 6) increases calcium wave fre-
quency in vascular smooth muscle cells of microvascular coronary arteries measured using Fluo-8. (A) The location of a smooth muscle cell line scan
(B) A raw data trace of normalized Fluo-8 florescence (F/F0) in response to neuropeptide-Y over the line scan and at three separate points (red, or-
ange, and blue). This is prevented by the Y1 receptor antagonist (BIBO3304, 1 lM, n = 6) as shown in (C). (D) Dose-response curve to neuropeptide-
Y (n = 6) demonstrating vasoconstriction in isolated, pressurized microvascular coronary arteries. This is prevented by the Y1 receptor antagonist
(BIBO3304, 1 lM, n = 6), without altering basal myogenic tone (E). (F) Neuropeptide-Y (250 nM, n = 6) causes a significant increase in coronary vas-
cular resistance in the Langendorff heart and this is prevented by the Y1 receptor antagonist BIBO3304 (1 lM, n = 6), but not the Y2 receptor antag-
onist BIIE0246 (1 lM, n = 6).
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venous NPY levels, although there was a strong trend. In a separate
cohort of STEMI patients, we have found that those with angiographic
no-reflow, lack of electrocardiographic ST-resolution, CFR <1.5, or
IMR >33 had significantly higher peripheral venous NPY levels over
the first 48 h from admission12 although we did not measure CS levels
or assess subsequent myocardial damage and prognosis.
Mechanism of microvascular
vasoconstriction
We hypothesize that maintained microvascular vasoconstriction
post-PPCI may contribute to a larger infarct size, worse left
ventricular function, and poorer prognosis and that NPY may be a
key mediator of this. Other substances have also been implicated
including endothelin-1,26 thromboxane-A2, and B-type natriuretic
peptide.1 The effect of NPY on small to medium arteries has been
studied in a variety of vascular beds10 although little is known about
the action of NPY in the coronary circulation. NPY produces vaso-
constriction in human epicardial coronary arteries by potentiating
norepinephrine mediated vasoconstriction.27 However, whether
NPY vasoconstricts the coronary microvasculature (which lack
alpha1 adrenergic receptors) has not previously been studied, and
these vessels are key to reperfusion post-PPCI. We directly demon-
strate that NPY causes a dose-dependent vasoconstriction of micro-
vascular coronary arteries and a rise in coronary vascular resistance
in the whole heart.
There are several potential mechanisms by which NPY may induce
vasoconstriction including:
i. Inhibiting cAMP dependent vasodilatory signalling (e.g. beta2 adrener-
gic receptors) via Y1 receptor coupling to inhibitory G proteins.
28
ii. Direct mobilization of sarcoplasmic reticulum calcium through a
phospholipase C—IP3 dependent pathway coupled to the Y1
receptor.28
iii. Indirectly through the release of endothelin-1 via the Y2 receptor.
29
Endothelin-1 is a potent vasoconstrictor of small resistance vessels
in the coronary circulation and several studies have found an associ-
ation between peripheral venous endothelin-1 levels and coronary
no-reflow post-STEMI.26 Although NPY has been shown to cause
endothelin-1 release in endocardial endothelial cells via a Y2 receptor
dependent pathway,29 we observe no correlation between CS NPY
Figure 3 Neuropeptide-Y Y1 receptor antagonism and infarct
size. (A) Examples of single ventricular slices at the mid ventricular
level which have undergone staining with Evans blue (to identify tis-
sue outside the area at risk) and triphenyltetrazolium chloride to
identify the infarct area. The later is very pale pink in the top images
and red in the bottom images as identified using ImageJ software. (B)
Neuropeptide-Y (250 nM, n = 10) significantly increases infarct area
in relation to the area at risk during ischaemia reperfusion in the
Langendorff heart compared to control (n = 10). This is blunted by
the Y1 receptor antagonist BIBO3304 (1 lM, n = 6). The area at risk
in relation to the total heart area was similar between groups (con-
trol 60.8 ± 7.4%, n = 10; neuropeptide-Y 60.7 ± 9.2%, n = 10;
BIBO3304þNPY 62.3 ± 10.7% n = 6).
Figure 4 Human coronary microvasculature Y1 receptor expres-
sion. Neuropeptide-Y Y1 receptor expression (in yellow) on vascu-
lar smooth muscle cells within the media of a pressurized human
coronary micro-artery. Lack of staining in the adventitia and intima
of the same vessel is shown for comparison. Nuclear staining in
blue, elastin in grey. Representative of three arteries.
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and endothelin-1 levels. Moreover, the increase in coronary vascular
resistance in response to NPY could not be prevented by a Y2 recep-
tor antagonist. A Y1 receptor antagonist did not on its own cause
vasodilatation or decrease coronary vascular resistance suggesting no
background beta2 receptor stimulation making Gi signalling unlikely.
In microvascular arteries, we directly observe the mobilization of
intracellcular calcium stores suggesting that Y1 receptor signalling is
most likely coupled to a phospholipase C-IP3 dependent pathway.
Limitations
This is a small mechanistic study that lacks statistical power and stud-
ies in large cohorts will be required to further investigate the relation-
ship with overall prognosis. Given the positive correlation between
peripheral venous and CS NPY levels, it may be that the same associ-
ations we describe for CS NPY also apply to peripheral venous levels
if there was a larger sample size. We also did not measure cardiac
NPY release via a CS-arterial NPY difference. By the time of sample
acquisition, CS and venous NPY levels appear to have equilibrated
and therefore a CS-arterial difference will have a low sensitivity. The
coronary microvasculature post-PPCI will be exposed to NPY
released locally as well as from circulating blood, and the combined
concentration will determine its overall physiological response. We
feel that this is best reflected in the overall CS concentration rather
than a CS-arterial difference.
Clinical implications
Given our clinical observations regarding CS NPY levels in STEMI
patients, the fact that the Y1 receptor antagonist BIBO3304 could
limit infarct size during ischaemia reperfusion in the rat, and the pres-
ence of the Y1 receptor on human coronary micro-arteries, we
speculate that Y1 receptor antagonism may be beneficial post-
revascularization by PPCI. This may help relieve microvascular con-
striction, restore blood flow, minimize infarct size, and improve ejec-
tion fraction if there is a reversible component to the obstruction. It
is also possible that NPY may play a role in the remodelling process
itself.10 The competitive Y1 receptor antagonist AR-H040922 has
been administered as an intravenous infusion in patients with SA but
did not influence exercise induced ischaemia at the dose used.30 This
is unsurprising given that SA is due to flow limiting epicardial coron-
ary artery stenosis, rather than microvascular dysfunction. Whether
this or similar compounds can improve microvascular function, re-
duce infarct size, and improve prognosis in the context of PPCI
remains to be established.
Supplementary material
Supplementary material is available at European Heart Journal online.
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